Skip to main content
Luye Pharma Group Limited logo

Luye Pharma Group Limited — Investor Relations & Filings

Ticker · 2186 HKEX Manufacturing
Open in API
Filings indexed 1,503 across all filing types
Latest filing 2024-08-09 Declaration of Voting R…
Country HK Hong Kong
Listing HKEX 2186

About Luye Pharma Group Limited

http://www.luye.cn

Luye Pharma Group is an international pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative medications, novel formulations, and biopharmaceutical products. The company's core strategy emphasizes advanced drug delivery systems, including microspheres, liposomes, and transdermal technologies, to enhance therapeutic efficacy and patient compliance. Luye Pharma maintains a strong focus on key therapeutic areas, particularly the Central Nervous System (CNS). Its portfolio includes proprietary products such as Roxinlin® (Toludesvenlafaxine extended-release tablets) and various long-acting injectable antipsychotic formulations, positioning the group as a global pharmaceutical enterprise.

Recent filings

Filing Released Lang Actions
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 9 AUGUST 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the poll results from the Annual General Meeting (AGM) held on 9 August 2024. It details the voting outcomes on various resolutions including receiving the audited financial statements, re-election of directors, appointment of auditors, and share mandates. The document does not contain the full financial report or detailed financial statements but rather the official voting results from the AGM. It explicitly states it is the "Poll Results of the Annual General Meeting" and includes vote counts and percentages. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is about 5075 characters, which is sufficient to include detailed voting results but not a full report. Therefore, the correct classification is DVA with high confidence.
2024-08-09 English
VOLUNTARY ANNOUNCEMENT - APPROVAL OBTAINED FOR INITIATING CLINICAL TRIALS FOR Innovative Dual TAAR1/5-HT2CR Agonist (LY03020)
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Luye Pharma Group Ltd. regarding the approval obtained to initiate clinical trials for a new drug (LY03020). It is an announcement of a regulatory milestone related to drug development, not a financial report, earnings release, or management discussion. The document is relatively short (4616 characters) and does not contain financial statements or detailed financial data. It is not an Annual Report, Interim Report, or Earnings Release. It is also not a regulatory filing in the sense of compliance documents or certifications. The content focuses on a clinical trial approval, which is a material event but does not fit into categories like M&A, capital update, or governance. Given the nature and length, this is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2024-08-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 July 2024. It details movements in authorised/registered share capital, issued shares, treasury shares, convertibles, and confirms compliance with listing rules. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting monthly share capital and share movement information. It is not a financial report like an annual or interim report, nor is it an earnings release or management discussion. It is a regulatory filing reporting share capital and securities movements as required by listing rules. The document length is 8317 characters, which is substantive but the content is regulatory in nature, not a report or announcement of a report. Therefore, the best fitting category is Regulatory Filings (RNS).
2024-08-05 English
Monthly Return of Equity Issuer on Movements in Securities
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 July 2024. It details movements in authorised/registered share capital, issued shares, share options, and confirms compliance with listing rules. It is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, focusing on share capital and share movements rather than financial performance or management commentary. The document is about share capital changes and confirmations related to securities issuance and treasury shares, which aligns with announcements regarding share capital changes rather than a full financial report or earnings release. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA). The document length (8605 characters) and detailed content support it being a substantive report on share capital movements, not just an announcement of a report or a certification.
2024-08-02 English
VOLUNTARY ANNOUNCEMENT - ERZOFRI (PALIPERIDONE PALMITATE) EXTENDED-RELEASE INJECTABLE SUSPENSION APPROVED BY THE FDA FOR TREATMENT OF SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER
Capital/Financing Update Classification · 85% confidence The document is a voluntary announcement by Luye Pharma Group Ltd. regarding the FDA approval of their drug ERZOFRI for treatment of schizophrenia and schizoaffective disorder. It contains detailed product information, safety warnings, clinical trial summary, and marketing approval details. There are no financial statements, earnings data, or management discussion of financial results. The document is not a full annual or interim report, nor is it a regulatory filing or certification. It is an announcement of a significant product approval event, which relates to company operations and product development rather than financial or governance matters. This fits best under the category of a Capital/Financing Update (CAP) as it relates to a major product approval that can impact company valuation and capital markets perception, although it is voluntary and not a financing per se. However, since the document is an announcement of a significant corporate development (FDA approval of a drug), and not a financial report or regulatory filing, the best fitting category is Capital/Financing Update (CAP).
2024-07-28 English
DISCLOSEABLE TRANSACTION THIRD PARTY INVESTMENT IN SHENZHEN LUYE
Capital/Financing Update Classification · 95% confidence The document is an announcement by Luye Pharma Group Ltd. regarding a discloseable transaction involving a third-party investment in Shenzhen Luye. It details the terms of the investment agreement, including the investment amount, equity interests, conditions precedent, repurchase options, valuation and profit undertakings, and board representation rights. The content focuses on a capital investment transaction and related contractual terms rather than financial results, audit opinions, management changes, or regulatory certifications. It is not a full financial report, earnings release, or management discussion. The document is a detailed announcement of a financing transaction and equity investment, which fits the category of Capital/Financing Update (CAP). The length and detail confirm it is not a brief announcement or a report publication notice, but a substantive transaction disclosure.
2024-07-23 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.